Full Title
Relapsed or Refractory Multiple Myeloma: Dose Escalation and Expansion of Etentamig in Combination with a CELMoD agentPurpose
Researchers want to see if combining etentamig (ABBV-383) with iberdomide is a safe treatment for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. The researchers will assess different doses of these drugs to find the best dose for patients.
Etentamig is a bispecific antibody. It binds to one protein on cancer cells and to another on immune cells called T cells. Etentamig may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor. It is given intravenously (by vein).
Iberdomide is already used to treat multiple myeloma. It works against cancer by helping to change or control the function of the immune system. Iberdomide is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have multiple myeloma that came back or keeps growing after prior treatment.
- Have recovered from the serious side effects of previous treatments before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information about this study or to see if you can join, please call Dr. Neha Korde’s office at 646-608-3708.